This study focuses on patients with Acute Myeloid Leukaemia, a type of blood cancer that affects the bone marrow and blood cells. The study aims to compare two different treatment approaches for this disease. One approach uses venetoclax (also known as ABT-199) combined with low-dose cytarabine, while the other approach uses intensive chemotherapy that includes daunorubicin hydrochloride and gemtuzumab ozogamicin.
The first treatment option involves taking venetoclax tablets by mouth along with cytarabine given through injections or infusions. The second treatment option consists of intensive chemotherapy medications given through intravenous infusions. The study will monitor how well each treatment works in preventing the return of the disease and helping patients achieve remission, which means there are no detectable cancer cells.
During the study, patients will receive treatment for up to 24 months. Throughout this time, doctors will regularly check the patient’s health status, perform blood tests, and monitor for any side effects. The study will track how long patients remain free from disease progression and measure their overall survival time. Quality of life and general health status will also be assessed at various points during the study period.



Denmark